I'm content to wait it out. There's enough here to support the current share price. It occurs to me that the company must be showing up on some big pharma radar. I think it's ripe for a buyout barring problems we're not aware of.
If NP did not tell you the efficacy info would be released last week you would not be disappointed today. If he originally said I will release it when it is tabulated our expectations would have been better managed. Now it is a struggle to show impact with good news last night and good news today. Should not be this hard.
Everyday it is looking more and more that it will be a three way punch of uplist, then a day or so will pass, then fda approval for one indication, then approval for the other. Which price wise this would probably be the best.